10-Q · August 13, 2026
The supplied excerpt does not contain the current quarter’s income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so revenue, margins, EPS, free cash flow, working-capital trends, and…
10-Q · Filed November 12, 2026 · Our reading of the company's report
The latest report
Q3 revenue of $695.5 million exceeded the $681.1 million consensus estimate, while diluted EPS of $0.20 matched expectations and improved from both the prior quarter and prior year. The filing highlights a substantial…
Q3 revenue of $695.5 million exceeded the $681.1 million consensus estimate, while diluted EPS of $0.20 matched expectations and improved from both the prior quarter and prior year. The filing highlights a substantial but still meaningful interest-rate exposure, with $1.5 billion of variable-rate debt and approximately $121.3 million unhedged. No material risk-factor changes were reported, and controls were deemed effective as of October 3, 2026; the supplied 10-Q text does not include explicit quantitative guidance.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Q3 revenue was $695.5 million, $14.4 million above the $681.1 million consensus estimate. Revenue increased from $670 million in Q2 2026 and $622 million in Q3 2025.
Diluted EPS was $0.20, matching the $0.20 consensus estimate and increasing from $0.18 in Q2 2026 and $0.06 in Q3 2025.
The company had $1.4 billion of aggregate interest-rate-cap notional as of October 3, 2026, covering variable-rate debt exposure and limiting near-term rate sensitivity.
Management concluded that disclosure controls were effective as of October 3, 2026, and reported no changes in internal control that materially impacted, or were reasonably likely to materially impact, reporting during the quarter.
Outstanding variable-rate debt was $1.5 billion as of October 3, 2026. A 100-basis-point increase in rates on approximately $121.3 million of unhedged variable-rate debt would increase annual interest expense by approximately $1.7 million.
The company paid an $8.7 million premium for an additional interest-rate cap effective February 28, 2027, with a 5.25% cap rate and $880.0 million of notional amount. This replaces an expiring cap and indicates continuing refinancing and hedging costs.
The filing states there were no material changes to the risk factors in the January 3, 2026 Form 10-K. However, the filing also notes that controls provide only reasonable—not absolute—assurance as of October 3, 2026, leaving residual error and fraud risk.
The supplied 10-Q text does not provide explicit quantitative revenue or EPS guidance. Separately, the prior 8-K analysis reported raised 2026 revenue guidance to greater than $2.695 billion and Adjusted EBITDA guidance to greater than $374 million.
The supplied excerpt does not contain the current quarter’s income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so revenue, margins, EPS, free cash flow, working-capital trends, and…
Aveanna Healthcare reported strong Q1 2026 results with revenue of $647.9 million, a 15.9% increase from $559.2 million in Q1 2025, surpassing expectations. Adjusted EPS reached $0.19, well above the consensus estimate…
Aveanna reports strong 2025 operating performance with revenue of $2,433,000,000 (sum of 2025 quarters), gross margin expansion and an EPS turnaround to $1.05 for the year driven by Q4 2025 revenue of $662,480,000 and…
Aveanna reported third-quarter revenue of $621.9M (up $112.9M or 22.2% YoY) driven in part by the June 2, 2025 Thrive acquisition. Gross margin was 32.6% and operating margin 8.6%, producing operating income of $53.6M…
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
The free pages stop at the last full session. Trader shows every trade as it prints.